Late breaking results from the phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate non ...
Abdullah also attributed GSK’s willingness to go all-in on mo-rez on the leadership of Luke Miels, who stepped up as CEO of ...
AbbVie today announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting (San Juan, ...
SAN JUAN, PUERTO RICO -- A novel regimen for platinum-resistant ovarian cancer solidified its role as a treatment option with ...
11h
How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates
Corcept Therapeutics is back in focus as analysts adjust price targets, with one bearish reset to US$67 from US$105 standing out against a backdrop of other target increases. These moves line up with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results